Scalper1 News
Biotech United Therapeutics (UTHR) missed Q4 sales estimates and reported higher-than-expected expenses Tuesday, sending shares down 1% in midday trading on the stock market today. The company said sales totaled $289 million, up 19% from the year-earlier quarter but missing analysts’ consensus by $6 million. The shortfall came in its lead drug, Remodulin, a treatment for pulmonary arterial hypertension. Its sales were about $7 million short of Scalper1 News
Scalper1 News